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Abstract
Background: We explored the views of key stakeholders to identify the ethical challenges of pragmatic trials
investigating pharmaceutical drugs. A secondary aim was to capture stakeholders’ attitudes towards the
implementation of pragmatic trials in the drug development process.
Methods: We conducted semistructured, in-depth interviews among individuals from different key stakeholder
groups (academia and independent research institutions, the pharmaceutical industry, regulators, Health Technology
Assessment (HTA) agencies and patients’ organizations) through telephone or face-to-face sessions. Interviews were
structured around the question “what challenges were experienced or perceived during the design, conduct and/or
review of pragmatic trials.” Respondents were additionally asked about their views on implementation of pragmatic
trials in the drug development process. Thematic analysis was used to identify the ethically relevant features across
data sets.
Results: We interviewed 34 stakeholders in 25 individual sessions and four group sessions. The four perceived challenges
of ethical relevance were: (1) less controlled conditions creating safety concerns, (2) comparison with usual
care potentially compromising clinical equipoise, (3) tailored or waivers of informed consent affecting patient
autonomy, and (4) minimal interference with “real-world” practice reducing the knowledge value of trial results.
Conclusions: We identified stakeholder concerns regarding risk assessment, use of suboptimal usual care as a
comparator, tailoring of informed consent procedures and ensuring the social value of pragmatic trials. These concerns
increased when respondents were asked about pragmatic trials conducted before market authorization.
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Background
The majority of randomized controlled trials (RCTs) in
drug research are explanatory trials that focus on drug
safety and efficacy [1, 2]. They are currently accepted as
the highest source of evidence for market authorization
decisions by regulatory bodies. However, explanatory ap-
proaches provide limited knowledge about how newly
marketed drugs work once applied under “real-world”
conditions and/or when compared with existing treat-
ments for the same condition in clinical practice [3, 4].
The lack of generalizability in drug RCTs has led to a
knowledge gap between what we know about the iso-
lated biological effects of a pharmaceutical compound
and what we know about its comparative effectiveness in
daily medical practice [5–9]. In 1967, Daniel Schwarz
and Joseph Lellouch published their landmark paper in
which they differentiate between explanatory and prag-
matic RCTs [10]. The authors noted that too often trialists
were not properly addressing their research questions due
to failure to match their trial design to the type of answers
they were seeking. According to the authors, the explana-
tory approach should be used when the aim is to obtain in-
formation about whether a treatment works under ideal
conditions. Hereto, a highly selected study population is re-
quired and extraneous effects (such as the placebo effect)
ought to be ruled out. The pragmatic approach, on the
other hand, has the aim of directly informing health care
professionals by comparing treatments under the condi-
tions they would be applied in practice (which includes ex-
traneous effects) [11]. In pragmatic research, existing
treatments can be tested against one another for their com-
parative effectiveness in real life, or new treatments are
compared with (a variety of) usual care for a specific condi-
tion. Because of the type of questions they seek to answer,
pragmatic trials generate so-called “real-world evidence”
which has potential to overcome the current knowledge
gap between drug efficacy and effectiveness.
Though no trial is completely explanatory nor com-
pletely pragmatic, trial designs can be assessed as being ei-
ther more explanatory (idealized circumstances) or more
pragmatic (resembling usual or real-world care) within a
continuum [12]. A trial that does not apply strict exclusion
criteria (to better reflect the real-world population), that
recruits patients with no more effort than would be used
to engage patients in usual care and that allows physicians
considerable flexibility in how they deliver the interven-
tion, can be called more pragmatic than explanatory.
Recent collaborative initiatives to facilitate the conduct
of pragmatic trials consist of the National Institutes of
Health (NIH) Health Care Systems Research Collabora-
tory [13] and the US Patient-Centered Clinical Research
Network (PCORnet) [14]. In general terms, their mission
is to increase the quality and reduce the costs of clinical
research through stakeholder engagement and use of
large amounts of health data. Pragmatic trials thus far have
almost always been discussed as post-market authorization
research. This renders pragmatic trials for many almost syn-
onymous to pragmatic comparative effectiveness trials.
However, real-world evidence on the comparative effective-
ness of drugs can in principle also be collected by pragmatic
trials in earlier phases of the drug life cycle. The Innovative
Medicines Initiative's (IMI) multi-stakeholder GetReal Con-
sortium has the objective of exploring new methods to in-
corporate real-world evidence earlier into the process of
drug development to better inform health care decision-
makers about the real-world effectiveness of new drugs at
market authorization [15].
Though regulatory bodies do not demand real-world
studies for all approved products per se, the European
Medicines Agency (EMA) does support the goals of prag-
matic trials through the development of so-called “adaptive
pathways.” Adaptive pathways, according to the EMA, is a
scientific concept for drug development which allows for
early and progressive patient access to new drugs through
conditional licensing, which requires real-world evidence
collection to support clinical trial data through an iterative
process [16]. For conceptual clarity, we refer to pragmatic
trials as RCTs that are “(d)esigned for the primary purpose
of informing decision-makers regarding the comparative
balance of benefits, burdens and risks of a biomedical or
behavioral health intervention at the individual or popula-
tion level” (a definition that does not distinguish between
pre- and post-market authorization research) [17]. We use
real-world comparative effectiveness as a measure that can
be evaluated both before and after market authorization of
the tested drug, though we acknowledge that comparative
effectiveness research (CER) is typically conducted with
standard of care treatments.
Considering recent initiatives to implement pragmatic
trials in routine health care settings—especially in earlier
phases of the drug life cycle—parallel ethical evaluation
appears warranted [18]. Such evaluation seems to become
even more compelling as recent debate has particularly fo-
cused on the ethical acceptability of pragmatic trials in
terms of altering informed consent requirements [19], the
inclusion of vulnerable populations [20], determining ad-
equate oversight practices [21], and the harms and bene-
fits patients face in pragmatic trials [22]. In the process of
articulating the ethical challenges of pragmatic trials with
pharmaceutical drugs – especially when implemented in
drug development – stakeholders’ views are an important
source of information.
We performed a qualitative study to obtain insight into
stakeholders’ views on the ethical challenges of pragmatic
trials comparing pharmaceutical treatments. To trace
potential ethically relevant differences between pre- and
post-market authorization pragmatic trials, a secondary
aim was to capture stakeholders’ attitudes towards the
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implementation of pragmatic trials in drug development.
This study was undertaken as part of the IMI GetReal Con-
sortium [15].
Methods
Study design and setting
This descriptive qualitative study aims to identify the expe-
riences, perceptions and attitudes from the point of view of
key stakeholders to explore the ethical challenges of
pragmatic clinical trials investigating pharmaceutical drugs.
Interviewees were identified from global stakeholders
involved in the conduct of pragmatic trials and real-world
studies, including stakeholders within academia, nonprofit
research institutions, contract research organizations
(CROs), the pharmaceutical industry, regulatory authorities,
health care insurers and Health Technology Assessment
(HTA) agencies as well as patient organizations. Table 1
provides a description of stakeholder characteristics. Since
experience with pragmatic trials in this field is relatively
scarce, respondents were identified by means of purposeful
sampling. In total 42 stakeholders were approached by
email for interviews; of these, two stakeholders declined an
interview due to time constraints and six of them were
nonresponders. Semistructured, in-depth interviews were
conducted face-to-face or, when distance was a problem
(e.g., for respondents located outside Europe), by telephone
or through an online connection. Group interviews were
set up with respondents who were involved in the same
projects within one company or institution.
Selection of participants
An invitation email with an information sheet was sent
to target participants identified through the network of
the IMI GetReal Consortium, and by following recom-
mendations from the interviewees (so-called snowball
sampling) [23]. Stakeholders were first asked to describe
their experience with either designing, conducting or
assessing real-world studies in general or, more specific-
ally, with pragmatic clinical trials. Subsequently, they
were asked to elaborate on any relevant challenges or
hurdles that were faced during the process. These chal-
lenges could either pertain to specific pragmatic design
aspects as well as to more general complexities throughout
the whole process of designing, conducting or assessing a
pragmatic trial. When a respondent put forward a study
that he or she was involved in which was relevant in terms
of ethical challenges, this study was pinpointed for further
enquiry if needed. Respondents were, in addition, asked to
specifically reflect on implementation of pragmatic trials
before regulatory approval of the test intervention. The de-
sign of the Salford Lung Study was described to stake-
holders as an example of a pre-market authorization
pragmatic trial (see Additional file 1) [24]. Recruitment was
terminated when saturation was reached, indicating that
no new thematic content was found [25].
All interviews were conducted between April and
October 2014. They were conducted by a trained
interviewer (SK) and took approximately 45–60 min. All
interviews were audio-recorded with permission of the
interviewees and transcribed verbatim. According to the
Dutch Medical Research Involving Human Subjects Act,
this type of study is exempt from ethical review. Verbal
consent was obtained from all respondents prior to the in-
terviews. The anonymity of respondents and institutions
was maintained in the interview transcripts.
Analysis and reporting
Transcripts of the interviews were coded in NVivo
qualitative data analysis software (version 10, QSR Inter-
national Pty Ltd.). Thematic analysis was used to identify
ethical considerations across data sets [26]. All interview
transcripts were coded by SK. For validation purposes,
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14 out of 29 interviews were double-coded by two add-
itional reviewers (GvT and AM), after which any discrep-
ancies were discussed until consensus was reached. We
used the consolidated criteria for reporting qualitative
research (COREQ) checklist to guide the conduct, ana-
lysis and reporting of this study [27]. See Additional file
2 for the COREQ checklist.
Results
Thirty-four stakeholders were interviewed in 25 individ-
ual interviews and four group interviews with a response
rate of 34/42 (81 %). After analysis of the interview data,
we identified four ethically relevant themes from the re-
spondents’ views on the ethical challenges of pragmatic
trials investigating pharmaceutical drugs.
Less controlled conditions create safety concerns
Respondents believed that pragmatic trials do not have
the degree of control that is required for more trad-
itional RCTs, predominantly due to lack of a highly dir-
ective study protocol that physicians are instructed to
follow. Physicians were thought to have considerable
flexibility in how they prescribe the test drug in a prag-
matic trial, i.e., prescribing the test drug as they would
do with any newly marketed drug. It was also feared that
physicians might prescribe doses beyond a drug’s label
indication creating safety issues for the patients enrolled.
This raised critical questions with respect to the respon-
sibilities that investigators have towards protecting the
interests of the patients enrolled in a pragmatic trial, if
indeed conducted under less controlled conditions.
On pre-market authorization pragmatic trials, respon-
dents perceived less controlled conditions to be particu-
larly problematic, assuming that at these stages safety
and efficacy data for and clinical experience with the test
drug is limited. Stakeholders supposed that in a prag-
matic trial minimal interference in real-world conditions
is strived for, indicating that after randomization safety
and efficacy follow-up is performed in accordance with
usual practice. A sizeable collection of safety and efficacy
data was considered a precondition before a pre-market
authorization pragmatic trial could proceed ethically.
Nevertheless, it was expressed that—even in the pres-
ence of sufficient efficacy and safety data—patients
might not always be called in for regular check-ups and
adverse events may not be recorded accurately as
follow-up is left to the treating physician:
“It seems that having commitments to safety
monitoring, at an individual clinical level – like, that
people come back with some frequency – and also at
an aggregate level through data safety monitoring, is
really important… To say the obvious, you are dealing
with real people who have real medical needs, and if
there are alternatives available that are not what is
being tested in the trial, we absolutely need to be
responsible for the welfare of the people in our trial,
and keep track of their disease.” (Bioethicist on pre-
market authorization pragmatic trials)
Comparison with suboptimal usual care compromises
clinical equipoise
Respondents expressed that pragmatic trials could be-
come ethically challenging when they incorporate “usual
care” as a comparison group. Different interviewees
referred to the SUPPORT study where the comparator
arm (defined as “usual care”) consisted of a range of
practices across a spectrum [28]. Respondents stated
that if usual medical practice is used as a comparator
arm, it may expose subjects to less than optimal medical
care.
A respondent within the pharmaceutical industry
highlighted discussions with regulatory authorities about
including usual care treatments in a randomized trial that
were not believed to constitute the “standard of care” due
to either insufficient quality of the treatments or their sub-
optimal delivery. The respondent also expressed the view
that choosing a comparator that lacks quality would make
the trial results less informative:
“The aim of a pragmatic trial is to record what is
happening in real life; however, you may experience
that you cannot proceed ethically with a pragmatic
study when routine care is delivered poorly. That is
an issue we all have to think about. It is always a
matter of finding a balance between the real-world
and a more controlled, closely monitored setting in an
explanatory sense.” (Pharmaceutical industry member
with experience in clinical trial design and conduct)
Tailored or waivers of informed consent infringes patient
autonomy
Respondents stated that the real-world nature of prag-
matic trials can be limited by additional requirements
for research. If the informed consent procedure for a re-
search intervention is more elaborate than the way con-
sent is obtained for the same intervention in clinical
practice, a pragmatic trial becomes less “real-world,” as
was voiced by different interviewees. Patients were said
to behave differently if they are aware that they are par-
ticipating in a trial (also known as the Hawthorne effect).
In addition, the amount of paperwork and the time
needed to complete the informed consent procedure
were experienced to impede recruitment.
Some clinical investigators and bioethicists believed
that the informed consent procedure for a pragmatic
trial for marketed products could perhaps be tailored,
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though this would greatly depend on the particulars of
the study:
“I think that there is no question that for an unapproved
product you would always need informed consent, I
don’t want by implication to say that for approved
products that you never do. But I think that discussions
can be on the table and can be looked at by a case-to-
case basis, for a pragmatic trial for an approved product.”
(Bioethicist on the difference between pre- and post-
market authorization pragmatic trials)
Respondents imagined that for some post-market
authorization randomized research, informed consent per-
haps could even be waived when the context would render
it ethically acceptable. Justifications for waivers were
named to be selection bias and limited generalizability of
trial results. One bioethicist stated that, under certain spe-
cified circumstances, informed consent could be integrated
into a routine clinic visit. A patient representative believed
that when a patient’s treating physician asks for informed
consent for trial participation this would potentially en-
danger the patient’s trust in receiving the best possible care
from his or her physician. Another bioethicist questioned
what waivers would exactly look like, either a complete
waiver for informed consent or waivers for certain ele-
ments of the consent procedure.
Some interviewees expressed concerns that completely
waiving informed consent would infringe patient autonomy
as well as have a negative impact on patients’ trust in bio-
medical research. Some bioethicists stated that even if
randomization would not meaningfully affect patients’ clin-
ical outcome, they may have a legitimate base for preferring
one study arm over the other due to expected side effects or
dosing scheme. Bioethicists occasionally felt that researchers
proposed waivers of consent merely out of convenience:
“Whether waivers are justified in drug trials really
depends on the risks people bear, whether standard of
care is withheld, whether it really is reasonably
impossible to obtain consent in large patient numbers
as that is what is often argued… I mean, is that truly
so impossible? And is it impossible because of the
large patient numbers or because patients would be
unnecessarily burdened by the consent procedure?
There is a difference there… And I believe that we
should be really critical in reviewing waivers to assess
whether it is really impossible or whether the waiver
just acts as an excuse for the sake of convenience.”
(Bioethicist on waivers of consent for post-market
authorization pragmatic trials)
All interviewees expressed concerns for reducing in-
formed consent requirements for unapproved products
due to lack of real-world experience and the presumed
limited knowledge base in terms of safety and efficacy.
Minimal interference with real-world practice drives arms
to equivalence
According to some respondents, a pragmatic trial allows
a considerable degree of physician flexibility with regards
to altering patients’ treatment while retaining them in
the trial. Such flexibility was perceived to serve two
ends: first, to ensure that patients enrolled in a prag-
matic trial are treated optimally, and second, that a prag-
matic trial remains as pragmatic as possible. This means
that during a trial a patient can switch to an alternative
treatment to the one they were initially randomized to,
as would also be the case in real life. However, a clinical
investigator had observed in a number of cases that
allowing patients to switch in the course of their treat-
ment inherently had driven the study arms to equiva-
lence. In these cases, the intervention arm would then
not separate from the comparator:
“I would like to emphasize again this problem of very
pragmatic trials, which is the lack of separation
(between arms). Among all the (published) pragmatic
clinical trials (in the literature) – there aren’t that many
of them compared to the number of RCTs done – but of
the ones that are out there, I think only a couple out of
maybe a dozen were able to differentiate the arms.
Again, if you have confident physicians, intent-to-treat
analytic approaches and a very pragmatic protocol, give
it enough time, physicians doing what they typically
do, will end up driving the arms to equivalence.”
(Pharmaceutical industry member on industry-
sponsored pragmatic trials)
Different respondents commented on this phenomenon,
saying that in designing a pragmatic trial efforts should be
directed at ensuring that the trial results will be inform-
ative. Though respondents identified this issue as a pre-
dominantly operational challenge, we additionally label it
an ethical one as respondents seem to imply that such
trial results do not sufficiently contribute to science and
society.
Discussion
In this qualitative study we interviewed 34 stakeholders
to identify the experienced and perceived ethical chal-
lenges related to (early) implementation of pragmatic
clinical trials with pharmaceutical drugs. Design choices
approximating real-world conditions may be necessary
to answer a pragmatic research question, yet have been
shown to give rise to perceived ethical challenges in four
domains: (1) less controlled conditions creating safety
concerns, (2) comparison with suboptimal usual care
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compromising clinical equipoise, (3) tailored or waivers
of informed consent infringing patient autonomy, and
(4) minimal interference with real-world practice redu-
cing the knowledge value of the results. The majority of
the respondents believed that real-world evidence gener-
ation was valuable and necessary; however, pre-market
authorization implementation of pragmatic trials was
considered to increase ethical concerns as the investiga-
tional treatments would not yet have received regulatory
approval.
The first challenge relates to the less controlled, real-
world conditions in which a pragmatic trial is supposed
to be conducted. Safety concerns were expressed about
limited pre-trial data in pre-market authorization prag-
matic trials, which exposes the underlying question of
how much explanatory data needs to be available to con-
trol for risk of harm in more heterogeneous populations.
Other concerns related to physicians’ flexibility in deliv-
ering the test intervention in routine practice: lack of a
detailed study protocol or lack of protocol adherence was
questioned to adequately protect the safety of enrolled pa-
tients, more so in pragmatic trials before market
authorization. These concerns raise questions about the du-
ties and responsibilities of investigators: what should inves-
tigators do when they suspect or observe that some
patients in the test arm are not receiving optimal medical
care? Though safety concerns were expressed within a
pragmatic trial, none of the interviewees mentioned patient
safety in the absence of real-world evidence outside a trial
context. The current system moves from closely monitored
trials to the use of new interventions in clinical practice
with typically only minimal monitoring and limited, un-
structured collection of safety data. Pragmatic trials could
address this question of safety in routine care before allow-
ing widespread use. One could thus argue that pragmatic
trials are an important step towards increasing safe use of
new drugs among the real-world patient population and
can be viewed as a strong ethical reason to perform such
trials, particularly in situations where there is no efficacy or
safety data comparing two comparable treatments.
The second challenge consists of determining whether
it is justified to randomize patients to different treatment
patterns used in practice, especially when the trial is
conducted under real-world conditions (supposedly
under less control than in more traditional RCTs). It was
questioned whether usual care ought to be submitted to
randomized investigation when it consists of a range of
treatments (each displaying a different risk-benefit pro-
file) or when the treatment standard might be delivered
suboptimally in the real-world setting. Ethically, there
must exist a state of clinical equipoise about the net pre-
ferred medical treatment prior to randomizing patients
to different interventions [29]; however, respondents
echoed existing disputes about the adequacy of, or
evidence base for, the interventions proposed for a trial.
The ultimate goal of clinical trials is to meaningfully
contribute to the understanding of different treatment
effects, to which usual care comparisons have proven
challenging [30]. Kass and colleagues state that “substan-
tial evidence now points to the frequency and severity of
the clinical harms that patients experience as a conse-
quence of the medical errors and lack of supervision that
occur in clinical care” [31]. For Kass and colleagues,
however, the problem of underprotection in clinical care
acts as a powerful incentive to undertake improvement
efforts, such as comparative effectiveness research, di-
rected at establishing which of two or more widely used
treatments for the same indication works best for which
patients.
Third, respondents acknowledged that informed con-
sent procedures for post-market authorization pragmatic
trials might not necessarily be as extensive as for pre-
market authorization research. The more real-life a trial
is aspired to be, the less room there seems to be for
obtaining trial-specific informed consent (in accordance
with Good Clinical Practice Guidelines), as was verbal-
ized by respondents. Some investigators stated that the
mere act of asking consent from patients interferes with
real-life conditions. In order to be able to judge to what
extent research consent is truly intrusive, we remark that
is important to have an accurate understanding of how
consent is obtained for a specific intervention in clinical
practice. In the literature, modified consent has been sug-
gested for certain pragmatic trials [19, 31–35]. For some
pragmatic trials with standard of care treatments, even
waivers have been proposed [36]. These suggestions have
sparked controversy which was paralleled in the inter-
views, displaying concerns of infringing patient autonomy.
Lastly, it was understood that if a patient or physician
enrolled in a pragmatic trial prefers an alternative treat-
ment to the one the patient was initially randomized to,
the patient can be allowed to change treatments while
staying in the study. Respondents experienced the
switching between study arms to drive the arms to
equivalence, which to some indicated that the trial re-
sults are less informative because the comparator does
not separate from the test drug. However, one could
argue that if no treatment effects are observed in a prag-
matic trial that allows switching, this is the real-life net
effect – a finding that provides science and society with
valuable answers to what in reality has no added benefit.
Grobbee and Hoes have observed that there is ample
confusion about the nature of pragmatic trials. They
state that “crossover” from one treatment arm to the
other can occur in both pragmatic and explanatory tri-
als, and that this may not be problematic as long as pa-
tients are analyzed by means of intention-to-treat
approaches [11]. Moreover, not allowing patients to
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switch treatments could lead to a delay in optimal care
for the individual patients enrolled as well as make pa-
tients less satisfied with the overall treatment they re-
ceived. However, if many crossovers are expected sample
size might need to be increased when the clinically
meaningful difference is smaller than the expected dif-
ference based on perfect protocol adherence. The ob-
served attitudes towards switching highlight the need to
specify what the value is that pragmatic trial results hold
for society and how their value can be optimized.
We note that this explorative, qualitative study had
some limitations. The difficulty with addressing the is-
sues of pragmatic trials in general is that the term “prag-
matic trial” refers to a range of RCTs across a
continuum, each trial displaying different design features
and each testing a different type of intervention. Due to
the exploratory nature of our study we did not narrow
down towards respondents what we understood to be a
pragmatic trial. Thus, stakeholders’ implicit assumptions
about design characteristics have likely influenced the
ethical challenges foreseen. This means that for some
pragmatic trials a raised challenge might be an issue,
whereas in others it is not: e.g., detailed protocols have
been observed in some trials that are self-described as
pragmatic but in others they may be completely absent.
From the interviews it also became clear that different,
sometimes erroneous assumptions about a pragmatic trial
were held. One respondent doubted whether a pragmatic
trial entailed randomization or not. In addition, experi-
ences, perceptions, opinions and speculation are ideally
separated in the analysis; however, in practice this is diffi-
cult to do. Nevertheless, we believe that our study provides
some valuable insights into the ethical issues of (early)
pragmatic trials and, in addition, exposes some persistent
difficulties in the discourse about pragmatic trials in terms
of their definition and design features.
Pragmatic clinical trials are welcomed as a valuable
means to obtaining the type of high-quality scientific evi-
dence that has the potential to directly enhance health care
decision-making [5–9, 17]. However, heated discussion still
continues on when and how to do it, both practically and
ethically. In a previous review of the literature, we found
that different attitudes towards the moral relevance of the
intertwinement of research and clinical care led to discus-
sions about whether current clinical trial regulations are
sufficient to protect the rights and interests of patients en-
rolled in pragmatic trials [21]. We believe that the experi-
ences and perceptions identified in this qualitative study
provide an important base for improving our understanding
of the ethical complexities of pragmatic trials and their po-
tential implementation in the drug development process.
Further work in terms of methodological analysis and eth-
ical evaluation is needed to flesh out which concerns pose
truly meaningful ethical challenges and which do not.
Conclusions
Recent collaborative initiatives are exploring ways to fa-
cilitate the (early) implementation of pragmatic trials in
routine health care settings. To do so effectively and re-
sponsibly, the ethical challenges of pragmatic trials need
to be identified and addressed. We performed a qualita-
tive study among stakeholders in the field of drug re-
search as a means to capture views of these challenges.
With respect to pragmatic trials with pharmaceutical
drugs, respondents perceived potential ethical challenges
relating to the presumed lack of control, the use of rou-
tine care as a comparator, the need for modified in-
formed consent and the power of a pragmatic trial to
detect differences when crossover is allowed. We identi-
fied the related ethical challenges of risk assessment,
evaluating the acceptability of usual care as a compara-
tor and the tailoring of informed consent procedures as
well as ensuring that the trial results have knowledge
value. Further exploration of these perceived concerns
and challenges is key to grasping the ethically relevant
features of the whole range of pragmatic trials, from
their implementation in drug development to their use
in post-market authorization research.
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